Sidley Represents HealthCare Royalty in Monetization Agreement for Modeyso Commercial Royalties

Sidley represented HealthCare Royalty (HCRx) in connection with its entry into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics, Inc. securityholders for an undisclosed percentage of royalties on commercial sales of Modeyso® (dordaviprone). Modeyso received U.S. Food and Drug Administration accelerated approval in August 2025 for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

More information about the transaction is available here.

The Sidley team was led by Adriana Tibbitts and Asher Rubin (Technology and Life Sciences Transactions), and included Cassidy Pomeroy-Carter (Technology and Life Sciences Transactions); Emily Chazen and Christine Seo (M&A); Adam Nelson (Global Finance); Sonia Barros and Istvan Hajdu (Capital Markets); Sara Duran (Private Equity); and Rachel Layne (Securities Enforcement and Regulatory).